Clinical Innovation in AML

Clinical Innovation in AML

Clinical Innovation in AML

In the last 4 years, 9 new therapies were approved for AML. Are you successfully navigating the rapidly shifting treatment paradigm?

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Courtney DiNardo, MD
    Associate Professor
    UT MD Anderson Cancer Center
    Houston, TX

    Research: AbbVie, Astex, BMS, Cleave, Foghorn
    Ownership Interest: Notable Labs (scientific advisory board with stock options)
    Consulting Fees: AbbVie, Astellas, BMS, Genmab, Kura, Novartis, Takeda

    Marina Y. Konopleva, MD, PhD
    Professor of Oncology and Molecular Pharmacology
    Montefiore Einstein Cancer Center
    Bronx, NY

    Research: AbbVie, Ablynx, Agios, Ascentage, AstraZeneca, Calithera, Cellectis, Eli Lilly, F. Hoffmann-La Roche, Forty Seven, Genentech, Rafael Pharmaceuticals, Sanofi, Stemline Therapeutics
    Receives royalties: Eli Lilly, Novartis, Reata Pharmaceuticals
    Patent Holder: Eli Lilly, Novartis, Reata Pharmaceuticals
    Consulting Fees: AbbVie, Amgen, F. Hoffmann-La Roche, Forty Seven, Genentech, Janssen, KisoJi, Stemline Therapeutics

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize appropriate molecular tests for patients with acute myeloid leukemia (AML)
    • Discuss risk stratification models for patients with AML
    • Summarize clinical trial data surrounding new therapies for patients with AML
    • Select therapies for patients with AML based on individualized factors
  • Target Audience

    This activity is designed to meet the educational needs of community and academic hematologist oncologists, medical oncologists, radiation oncologists, pathologists, pharmacists, nurse practitioners, physician assistants, nurses, and other HCPs treating patients with AML.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Expert Interview activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until 9/30/2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for .50 contact hours .05 CEUs  by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0006235-0000-22-036-H01-P. This learning activity is visually based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie Inc. and Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free